Physician profile
Timothy E Bael
NPI 1376605501
$3,018.00
in general payments reported to CMS, 2019-2025
26 companies · $278 in 2025
The $278 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $1,825 · 2021: $125 · 2022: $50.26 · 2023: $290 · 2024: $291 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809 · Education: $49.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.31 |
| Education | $49.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,800.00 | 2020 | |
| Pfizer INC. | $174.93 | 2019-2025 | |
| Boston Scientific Corporation | $142.28 | 2023 | |
| Novartis Pharmaceuticals Corporation | $105.95 | 2023-2025 | |
| Tempus Ai, INC | $100.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $77.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $77.22 | 2024-2025 | Lynparza, Calquence, Tagrisso |
| Array Biopharma INC | $73.33 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $43.20 | 2025 | Monoferric |
| Eisai INC. | $42.06 | 2021-2024 | |
| Janssen Biotech, INC. | $35.40 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $33.62 | 2022-2024 | Ojjaara |
| Genzyme Corporation | $32.32 | 2024 | |
| Merck Sharp & Dohme LLC | $30.17 | 2019-2020 | |
| Abbvie INC. | $29.40 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26.10 | 2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $25.70 | 2025 | |
| Sumitomo Pharma America, INC. | $23.93 | 2023 | Orgovyx |
| Seagen INC. | $22.39 | 2023 | Adcetris |
| Coherus Oncology, INC. | $21.84 | 2021 | |
| Emd Serono, INC. | $21.63 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.69 | 2024 | Givlaari |
| Kite Pharma, INC. | $17.77 | 2023 | |
| Genentech USA, INC. | $15.68 | 2019 | |
| Blueprint Medicines Corporation | $15.43 | 2024 | Ayvakit |
| Celgene Corporation | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.